CLRB

Cellectar Biosciences, Inc. (CLRB) | Rumor.io

Cellectar Biosciences

CLRB

Attention (50-day avg)0%

Attention rank (50-day avg)#2,931

Bullish sentiment (50-day avg)93%

Price to earnings ratio-0.22

Market capitalization17.3M

Earnings per share-2.21

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-21.8M

Social

What share of all stock conversation is about CLRB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 15

Cellectar Biosciences' Phase 1 study of Iopofosine I 131 in a peer-reviewed journal, Cancers, showed 84.6% of patients achieved stable disease or better, with manageable toxicity.
The study, which tested Iopofosine I 131 in 31 heavily pretreated relapsed/refractory multiple myeloma patients, supports continued development of the treatment as a novel targeted radiotherapeutic across multiple B-cell malignancies.
Cellectar Biosciences has received multiple FDA regulatory milestones for Iopofosine I-131, including Breakthrough, Orphan Drug, Rare Pediatric Drug, and Fast Track designations, and is eligible for a FDA Pediatric Review Voucher.

Generated by AI

Sentiment

Of the messages about CLRB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	80% -20	83.33% -16.67	85.91% +2.04
Bearish	0%	20% new	16.67% +16.67	14.09% -2.04

Bullish· May 6

Cellectar Biosciences has successfully transitioned from a struggling biotech to a fully funded P3 powerhouse with best-in-class 84% ORR and 18-month durability.
The company's Iopofosine has been granted Breakthrough, six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations by the FDA, and Priority Medicines (PRIME) designation by the EMA.
Cellectar Biosciences is expected to generate $400M in yearly sales with Iopofosine I-131 for WM, MM, and pHGG, and potentially $4B in pipeline sales for TNBC or Pancreatic.

Bearish· May 6

The company's stock price is expected to drop to $1.50-$2.00.
The stock is considered a "scam" and a "ponzi scheme" with a high likelihood of being delisted or experiencing a reverse split.
The stock's price is expected to decline significantly after a brief pop, with one post suggesting a drop to $2.25 and another to $1.75.

Generated by AI

Topics

Of the messages about CLRB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	31.56%
Technical Analysis	0%	0%	0%	27.17%
Earnings	0%	0%	0%	1.61%
Analysts	0%	0%	0%	20.67%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	18.99%

Earnings· May 10

The earnings call date for Cellectar Biosciences, Inc. (CLRB) is not yet updated.

Announcements· May 5

Cellectar Biosciences, Inc. reported positive 12-month follow-up data from Phase 2b CLOVER WaM study, demonstrating durable responses and efficacy of iopofosine I 131 in r/r Waldenström Macroglobulinemia, with 83.6% ORR and 61.8% MRR achieved.
The company secured up to $140 million in oversubscribed financing to fund a confirmatory study and accelerated approval bid, removing the funding cliff and covering the EMA filing for iopofosine I-131 in Waldenstrom macroglobulinemia.
Analyst estimates for the peak annual sales of Cellectar Biosciences' lead drug, iopofosine I-131, generally range between $200 million and $340 million.

Technical Analysis· May 5

$CLRB has shown a clear tape shift after an initial parabolic move, catching an initial rug pull and recycling after the open.
$CLRB needs to break the pennant and the VWAP at 5.32 to potentially bounce back into the 5s, with a 4.5 reclaim with volume being a key level to watch.
$CLRB's price action is currently in a downtrend, but it may change soon, with the 200 EMA on the 1-minute chart being a key level to watch, and the stock desperately needs to get back over it.

Generated by AI

Community

Of the messages about CLRB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	75%	84.21%	84%	49.63%
Newcomers	25%	15.79%	16%	50.37%

Regulars· Sep 5

$CLRB is expected to swing in the coming days, with a target price of $2.38.
Cellectar Biosciences has announced up to $103 million in private placement financing, a significant development for the company.
The stock has seen significant trading activity, with a complete float of 6.8M shares being traded in a single day.

Newcomers· May 6

New traders are focusing on the short-term price action of $CLRB, with some anticipating a move towards $3.77 and $4.30.
A significant concern among newcomers is the potential for $CLRB to crash if it breaks below its current support level of $2.70.
There is also a growing awareness among new traders that $CLRB's recent price drop was a result of a large dilution event, with the company issuing new shares at a discounted price.

Generated by AI

News

Cellectar plans Phase 3 trial, regulatory filing for WM treatment

1d agoInvesting.com

Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript

Detailed price information for Cellectar Biosciences Inc (CLRB-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow (NASDAQ:CLRB) 2026-08-18

2026-08-18. The following slide deck was published by Cellectar Biosciences, Inc.

1mo agoSeeking Alpha

Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...

1mo agoYahoo Finance

Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary

Moby summary of Cellectar Biosciences, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

1mo agoInvesting.com

Also Discussed

Investors talking about CLRB also mention

#	Name	Attention
1	B.O.S. Better Online Solutions Ltd.BOSC	0%0
2	Birks Group IncBGI	0%new
3	MRNS - Marinus Pharmaceuticals, Inc.	——
4	BCEI - Civitas Resources, Inc.	——
5	BLPH - Bellerophon Therapeutics, Inc.	——
6	Kura Oncology, Inc.KURA	0%+0
7	SemiLEDs CorporationLEDS	0%0
8	Harte Hanks Inc.HHS	0%new
9	SINO - Singularity Future Technology Ltd.	——
10	Pulmatrix Inc.PULM	0%0

Cellectar Biosciences, Inc.

Healthcare
Biotechnology

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on developing targeted cancer therapies and imaging agents. The company’s work centers on its proprietary phospholipid drug conjugate platform, which is designed to deliver therapeutic payloads directly to cancer cells while limiting exposure to healthy tissue. Its current portfolio includes radioconjugate and other oncology programs aimed at hematologic malignancies and solid tumors, along with imaging applications that support cancer detection and treatment planning. Cellectar Biosciences also pursues commercialization and research collaborations to advance its drug candidates through development. Headquartered in Florham Park, New Jersey, Cellectar Biosciences operates as a specialized cancer-focused company within the biopharmaceutical sector.

Website

Location

100 Campus Drive

Florham Park, NJ, 07932

United States

Social

What share of all stock conversation is about CLRB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 15

Cellectar Biosciences' Phase 1 study of Iopofosine I 131 in a peer-reviewed journal, Cancers, showed 84.6% of patients achieved stable disease or better, with manageable toxicity.
The study, which tested Iopofosine I 131 in 31 heavily pretreated relapsed/refractory multiple myeloma patients, supports continued development of the treatment as a novel targeted radiotherapeutic across multiple B-cell malignancies.
Cellectar Biosciences has received multiple FDA regulatory milestones for Iopofosine I-131, including Breakthrough, Orphan Drug, Rare Pediatric Drug, and Fast Track designations, and is eligible for a FDA Pediatric Review Voucher.

Generated by AI

Sentiment

Of the messages about CLRB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	80% -20	83.33% -16.67	85.91% +2.04
Bearish	0%	20% new	16.67% +16.67	14.09% -2.04

Bullish· May 6

Cellectar Biosciences has successfully transitioned from a struggling biotech to a fully funded P3 powerhouse with best-in-class 84% ORR and 18-month durability.
The company's Iopofosine has been granted Breakthrough, six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations by the FDA, and Priority Medicines (PRIME) designation by the EMA.
Cellectar Biosciences is expected to generate $400M in yearly sales with Iopofosine I-131 for WM, MM, and pHGG, and potentially $4B in pipeline sales for TNBC or Pancreatic.

Bearish· May 6

The company's stock price is expected to drop to $1.50-$2.00.
The stock is considered a "scam" and a "ponzi scheme" with a high likelihood of being delisted or experiencing a reverse split.
The stock's price is expected to decline significantly after a brief pop, with one post suggesting a drop to $2.25 and another to $1.75.

Generated by AI

Topics

Of the messages about CLRB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	31.56%
Technical Analysis	0%	0%	0%	27.17%
Earnings	0%	0%	0%	1.61%
Analysts	0%	0%	0%	20.67%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	18.99%

Earnings· May 10

The earnings call date for Cellectar Biosciences, Inc. (CLRB) is not yet updated.

Announcements· May 5

Cellectar Biosciences, Inc. reported positive 12-month follow-up data from Phase 2b CLOVER WaM study, demonstrating durable responses and efficacy of iopofosine I 131 in r/r Waldenström Macroglobulinemia, with 83.6% ORR and 61.8% MRR achieved.
The company secured up to $140 million in oversubscribed financing to fund a confirmatory study and accelerated approval bid, removing the funding cliff and covering the EMA filing for iopofosine I-131 in Waldenstrom macroglobulinemia.
Analyst estimates for the peak annual sales of Cellectar Biosciences' lead drug, iopofosine I-131, generally range between $200 million and $340 million.

Technical Analysis· May 5

$CLRB has shown a clear tape shift after an initial parabolic move, catching an initial rug pull and recycling after the open.
$CLRB needs to break the pennant and the VWAP at 5.32 to potentially bounce back into the 5s, with a 4.5 reclaim with volume being a key level to watch.
$CLRB's price action is currently in a downtrend, but it may change soon, with the 200 EMA on the 1-minute chart being a key level to watch, and the stock desperately needs to get back over it.

Generated by AI

Community

Of the messages about CLRB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	75%	84.21%	84%	49.63%
Newcomers	25%	15.79%	16%	50.37%

Regulars· Sep 5

$CLRB is expected to swing in the coming days, with a target price of $2.38.
Cellectar Biosciences has announced up to $103 million in private placement financing, a significant development for the company.
The stock has seen significant trading activity, with a complete float of 6.8M shares being traded in a single day.

Newcomers· May 6

New traders are focusing on the short-term price action of $CLRB, with some anticipating a move towards $3.77 and $4.30.
A significant concern among newcomers is the potential for $CLRB to crash if it breaks below its current support level of $2.70.
There is also a growing awareness among new traders that $CLRB's recent price drop was a result of a large dilution event, with the company issuing new shares at a discounted price.

Generated by AI

Cellectar Biosciences

Social

Jul 15

Bullish· May 6

Bearish· May 6

Earnings· May 10

Announcements· May 5

Technical Analysis· May 5

Regulars· Sep 5

Newcomers· May 6

Cellectar plans Phase 3 trial, regulatory filing for WM treatment

Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript

Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow (NASDAQ:CLRB) 2026-08-18

Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...

Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

Also Discussed

Cellectar Biosciences, Inc.

Company Information

Location

Cellectar plans Phase 3 trial, regulatory filing for WM treatment

Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript

Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow (NASDAQ:CLRB) 2026-08-18

Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...

Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

Also Discussed

Social

Jul 15

Bullish· May 6

Bearish· May 6

Earnings· May 10

Announcements· May 5

Technical Analysis· May 5

Regulars· Sep 5

Newcomers· May 6